Gene therapy for prostate cancer.
Prostate cancer is one of the leading causes of cancer deaths in the western hemisphere. A number of different gene therapy strategies are currently being evaluated. The ex vivo and many of the in vivo therapies involve stimulating a specific antitumor immune response. Autologous vaccines involving interleukin-2 (IL-2)- or granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced whole tumor cells showed great promise in animal models. Clinical trials of these and other vaccine strategies are underway. In vivo gene therapies involving the replacement of mutant tumor-suppressor genes, antisense strategies, and the insertion of suicide genes are also being evaluated in prostate cancer.
Hrouda
D
D
Department of Oncology, St George's Hospital Medical School, London, UK.
Perry
M
M
Dalgleish
A G
AG
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D018139:Simplexvirus; D013937:Thymidine Kinase
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016376:Oligonucleotides, Antisense; D013937:Thymidine Kinase